BMRN BioMarin (BMRN) Q2 FY26 earnings call
BioMarin delivered a standout second quarter, marked by robust revenue growth and the successful integration of Amicus, which is exceeding initial expectations for peak revenue and synergies. The company raised its full-year guidance for total revenue, VOXZOGO, and non-GAAP EPS, signaling strong momentum into the second half of the year. Strategic pipeline advancements, including a rapid sNDA submission for VOXZOGO in hypochondroplasia, underscore BioMarin's commitment to expanding its leadership in genetic conditions and driving future growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.